甲泼尼龙琥珀酸钠辅助治疗儿童肺炎支原体大叶性肺炎的疗效及安全性

Efficacy and safety of sodium methylprednisolone succinate in the adjuvant treatment of mycoplasma pneumoniae macrolobular pneumonia in children

目的:分析为肺炎支原体大叶性肺炎患儿采用甲泼尼龙琥珀酸钠进行辅助治疗的临床疗效及安全性。方法:选取江苏省睢宁县人民医院2019年1月至12月收治的90例肺炎支原体大叶性肺炎患儿作为研究对象。按随机数表法将其分为常规组和激素组。对常规组患儿进行常规治疗,在此基础上为激素组患儿采用甲泼尼龙琥珀酸钠进行治疗。然后对比两组患儿临床表现改善的时间、血清C-反应蛋白(CRP)的水平和不良反应的发生情况。结果:与常规组患儿相比,激素组患儿治疗后其各项临床表现改善的时间均更短,其血清CRP的水平更低,P<0.05。两组患儿不良反应的发生率相比,P>0.05。结论:为肺炎支原体大叶性肺炎患儿采用甲泼尼龙琥珀酸钠进行辅助治疗的临床疗效显著,可有效地降低其血清炎症因子的水平,且安全性较高。

Objective:To analyze the clinical efficacy and safety of methylprednisolone succinate in children with mycoplasma pneumoniae macrolobular pneumonia.Methods:90 children with mycoplasma pneumoniae macrolobular pneumonia admitted to Suining People’s Hospital in Jiangsu Province from January to December 2019 were selected as study subjects.They were divided into normal group and hormone group according to random number table method.The children in the conventional group received conventional treatment,on the basis of which the children in the hormone group were treated with sodium methylprednylsuccinate.Then,the time of clinical improvement,serum C-reactive protein(CRP)level and the occurrence of adverse reactions were compared between the two groups.Results:Compared with the conventional group,the time for improvement of all clinical manifestations was shorter in the hormone group after treatment,and the serum CRP level was lower(P<0.05).The incidence of adverse reactions between the two groups was P>0.05.Conclusion:Methylprednisolone sodium succinate has a significant clinical effect in children with mycoplasma pneumoniae macrolobular pneumonia.It can effectively reduce the level of serum inflammatory facto rs and is safe.